SABS vs. CRIS, FBIO, BOLT, MTEM, AMGN, VRTX, REGN, GILD, BIIB, and ALNY
Should you be buying SAB Biotherapeutics stock or one of its competitors? The main competitors of SAB Biotherapeutics include Curis (CRIS), Fortress Biotech (FBIO), Bolt Biotherapeutics (BOLT), Molecular Templates (MTEM), Amgen (AMGN), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Gilead Sciences (GILD), Biogen (BIIB), and Alnylam Pharmaceuticals (ALNY). These companies are all part of the "biotechnology" industry.
Curis (NASDAQ:CRIS) and SAB Biotherapeutics (NASDAQ:SABS) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, community ranking, dividends, risk, institutional ownership, valuation, profitability, media sentiment and analyst recommendations.
In the previous week, SAB Biotherapeutics had 5 more articles in the media than Curis. MarketBeat recorded 6 mentions for SAB Biotherapeutics and 1 mentions for Curis. SAB Biotherapeutics' average media sentiment score of 1.87 beat Curis' score of -0.19 indicating that Curis is being referred to more favorably in the media.
SAB Biotherapeutics has lower revenue, but higher earnings than Curis.
30.0% of Curis shares are owned by institutional investors. Comparatively, 7.8% of SAB Biotherapeutics shares are owned by institutional investors. 5.7% of Curis shares are owned by insiders. Comparatively, 26.0% of SAB Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Curis received 669 more outperform votes than SAB Biotherapeutics when rated by MarketBeat users. However, 76.00% of users gave SAB Biotherapeutics an outperform vote while only 67.65% of users gave Curis an outperform vote.
Curis presently has a consensus target price of $37.33, suggesting a potential upside of 260.36%. SAB Biotherapeutics has a consensus target price of $15.50, suggesting a potential upside of 487.12%. Given Curis' higher possible upside, analysts clearly believe SAB Biotherapeutics is more favorable than Curis.
Curis has a beta of 3.59, indicating that its share price is 259% more volatile than the S&P 500. Comparatively, SAB Biotherapeutics has a beta of 0.78, indicating that its share price is 22% less volatile than the S&P 500.
Curis has a net margin of -486.45% compared to Curis' net margin of -1,531.26%. Curis' return on equity of -109.90% beat SAB Biotherapeutics' return on equity.
Summary
Curis beats SAB Biotherapeutics on 9 of the 16 factors compared between the two stocks.
Get SAB Biotherapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SABS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SABS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
SAB Biotherapeutics Competitors List
Related Companies and Tools
